Your browser doesn't support javascript.
loading
Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System.
Nordgård, Oddmund; Brendsdal Forthun, Rakel; Lapin, Morten; Grønberg, Bjørn Henning; Kalland, Karl Henning; Kopperud, Reidun Kristin; Thomsen, Liv Cecilie Vestrheim; Tjensvoll, Kjersti; Gilje, Bjørnar; Gjertsen, Bjørn Tore; Hovland, Randi.
Afiliación
  • Nordgård O; Department of Hematology and Oncology, Stavanger University Hospital, 4011 Stavanger, Norway.
  • Brendsdal Forthun R; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021 Stavanger, Norway.
  • Lapin M; Department of Medical Genetics, Haukeland University Hospital, 5021 Bergen, Norway.
  • Grønberg BH; Section of Cancer Genomics, Haukeland University Hospital, 5021 Bergen, Norway.
  • Kalland KH; Department of Hematology and Oncology, Stavanger University Hospital, 4011 Stavanger, Norway.
  • Kopperud RK; Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
  • Thomsen LCV; Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, 7030 Trondheim, Norway.
  • Tjensvoll K; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.
  • Gilje B; Department of Microbiology, Haukeland University Hospital, 5021 Bergen, Norway.
  • Gjertsen BT; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.
  • Hovland R; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Cancers (Basel) ; 13(8)2021 Apr 13.
Article en En | MEDLINE | ID: mdl-33924696
Liquid biopsies have emerged as a potential new diagnostic tool, providing detailed information relevant for characterization and treatment of solid cancers. We here present an overview of current evidence supporting the clinical relevance of liquid biopsy assessments. We also discuss the implementation of liquid biopsies in clinical studies and their current and future clinical role, with a special reference to the Nordic healthcare systems. Our considerations are restricted to the most established liquid biopsy specimens: circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Both ctDNA and CTCs have been used for prognostic stratification, treatment choices, and treatment monitoring in solid cancers. Several recent publications also support the role of ctDNA in early cancer detection. ctDNA seems to provide more robust clinically relevant information in general, whereas CTCs have the potential to answer more basic questions related to cancer biology and metastasis. Epidermal growth factor receptor-directed treatment of non-small-cell lung cancer represents a clinical setting where ctDNA already has entered the clinic. The role of liquid biopsies in treatment decisions, standardization of methods, diagnostic performance and the need for further research, as well as cost and regulatory issues were identified as factors that influence further integration in the clinic. In conclusion, substantial evidence supports the clinical utility of liquid biopsies in cancer diagnostics, but further research is still required for a more general application in clinical practice.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Aspecto: Implementation_research Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Aspecto: Implementation_research Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Suiza